BridgeBio Oncology Therapeutics, Inc. (BBOT): Total Liabilities
$37.28M
As of 2025-12-31
$53.59M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.28M | +90.4% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $19.58M | n/m | 2026-03-05, Balance as of period end |
| 2023-12-31 | $396.5K | n/a | 2025-03-11, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $37.28M | +90.4% |
| Biohaven Ltd. (BHVN) | 2025-12-31 | $399.38M | +108.4% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $41.92M | +370.4% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $243.49M | +27.3% |
| Bicara Therapeutics Inc. (BCAX) | 2025-12-31 | $29.54M | +63.0% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $119.95M | +388.8% |
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $16.57M | +4.1% |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $21.14M | -2.7% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $210.17M | -7.7% |
Compare BBOT, BHVN, BGM, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗